Benitec Biopharma
BNTC
1 hedge funds and large institutions have $2.38M invested in Benitec Biopharma in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
40% less capital invested
Capital invested by funds: $3.97M → $2.38M (-$1.59M)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$864K |
BNTC Hedge Fund Activity: Q4 2015 in Review
1 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2015, worth a combined $2.38M — down 40% from $3.97M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BNTC and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $498K. The largest seller was RA Capital Management, exiting entirely with an estimated $864K sold.
- 1 institutional investor held Benitec Biopharma (BNTC) as of Q4 2015, down from 2 in Q3 2015.
- Funds reported $2.38M of Benitec Biopharma stock for Q4 2015, down 40% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q4 2015 and 1 closed out, a net change of -1 holder.
- The largest Benitec Biopharma buyer in Q4 2015 was Sabby Management, an estimated $498K added.
- The largest Benitec Biopharma seller in Q4 2015 was RA Capital Management, an estimated $864K sold.
Based on aggregated 13F filings for Q4 2015.